SCHEMBL20170935

SCHEMBL20170935

CCCCCCCCCNC(=O)c1csc(-c2ccccc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 2/20 0.61
HPGD P15428 2/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
HDAC1 Q13547 4/20 0.59
HDAC6 Q9UBN7 2/20 0.59
HDAC8 Q9BY41 1/20 0.59
ACKR3 P25106 2/20 0.57
TDP1 Q9NUW8 2/20 0.56
HDAC3 O15379 3/20 0.56
NAAA Q02083 1/20 0.55
TLR7 Q9NYK1 1/20 0.53
MAPT P10636 2/20 0.52
ATM Q13315 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
NPY1R P25929 1/20 0.52
NPY2R P49146 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3547707 1.00 HPGDS (0.61) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL3436271 0.90 HPGD (0.66) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL12789158 0.84 HPGD (0.69) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL7364347 0.84 HDAC1 (0.58) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL27965799 0.82 HDAC1 (0.65) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL27965984 0.82 RAB9A (0.66) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL27965978 0.82 RAB9A (0.61) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL2101661 0.82 HDAC3 (0.51) HPGDSHPGDHDAC1HDAC6HDAC8
SCHEMBL27966332 0.82 HPGD (0.66) HPGDSHPGDCYP1A2CYP3A4CYP2C9
SCHEMBL27966030 0.81 HPGDS (0.49) HPGDSHPGDCYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970334-B1 MACROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES BIOGEN MA INC (US) 2018-05-23 EP disclosed